JP7021301B2 - 無菌眼用水性プロピオン酸フルチカゾンａ型ナノ結晶懸濁液の調製方法 - Google Patents

無菌眼用水性プロピオン酸フルチカゾンａ型ナノ結晶懸濁液の調製方法 Download PDF

Info

Publication number
JP7021301B2
JP7021301B2 JP2020124238A JP2020124238A JP7021301B2 JP 7021301 B2 JP7021301 B2 JP 7021301B2 JP 2020124238 A JP2020124238 A JP 2020124238A JP 2020124238 A JP2020124238 A JP 2020124238A JP 7021301 B2 JP7021301 B2 JP 7021301B2
Authority
JP
Japan
Prior art keywords
weight
nanocrystals
fluticasone propionate
nanosuspension
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020124238A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021017449A (ja
JP2021017449A5 (enExample
Inventor
ジャン－ミシェル・ブコウスキー
アクシャイ・ナドカーニ
ホセ・エル・ボイヤー
ブリジット・デュケスロイ－チャクルン
トーマス・ナヴラティル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicox Ophthalmics Inc
Original Assignee
Nicox Ophthalmics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Ophthalmics Inc filed Critical Nicox Ophthalmics Inc
Publication of JP2021017449A publication Critical patent/JP2021017449A/ja
Publication of JP2021017449A5 publication Critical patent/JP2021017449A5/ja
Priority to JP2022015508A priority Critical patent/JP7494230B2/ja
Application granted granted Critical
Publication of JP7021301B2 publication Critical patent/JP7021301B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2020124238A 2019-07-23 2020-07-21 無菌眼用水性プロピオン酸フルチカゾンａ型ナノ結晶懸濁液の調製方法 Active JP7021301B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022015508A JP7494230B2 (ja) 2019-07-23 2022-02-03 無菌眼用水性プロピオン酸フルチカゾンａ型ナノ結晶懸濁液の調製方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962877599P 2019-07-23 2019-07-23
US62/877,599 2019-07-23
US201962942551P 2019-12-02 2019-12-02
US62/942,551 2019-12-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022015508A Division JP7494230B2 (ja) 2019-07-23 2022-02-03 無菌眼用水性プロピオン酸フルチカゾンａ型ナノ結晶懸濁液の調製方法

Publications (3)

Publication Number Publication Date
JP2021017449A JP2021017449A (ja) 2021-02-15
JP2021017449A5 JP2021017449A5 (enExample) 2021-12-23
JP7021301B2 true JP7021301B2 (ja) 2022-02-16

Family

ID=71738074

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020124238A Active JP7021301B2 (ja) 2019-07-23 2020-07-21 無菌眼用水性プロピオン酸フルチカゾンａ型ナノ結晶懸濁液の調製方法
JP2022015508A Active JP7494230B2 (ja) 2019-07-23 2022-02-03 無菌眼用水性プロピオン酸フルチカゾンａ型ナノ結晶懸濁液の調製方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022015508A Active JP7494230B2 (ja) 2019-07-23 2022-02-03 無菌眼用水性プロピオン酸フルチカゾンａ型ナノ結晶懸濁液の調製方法

Country Status (23)

Country Link
US (3) US11406596B2 (enExample)
EP (1) EP3769753B1 (enExample)
JP (2) JP7021301B2 (enExample)
KR (1) KR20220038443A (enExample)
CN (2) CN115120557B (enExample)
AU (1) AU2020317084A1 (enExample)
CA (1) CA3145055A1 (enExample)
CY (1) CY1124930T1 (enExample)
DK (1) DK3769753T3 (enExample)
ES (1) ES2905793T3 (enExample)
HR (1) HRP20220165T1 (enExample)
HU (1) HUE057416T2 (enExample)
LT (1) LT3769753T (enExample)
MD (1) MD3769753T2 (enExample)
MX (1) MX420447B (enExample)
PH (1) PH12022550003A1 (enExample)
PL (1) PL3769753T3 (enExample)
PT (1) PT3769753T (enExample)
RS (1) RS62932B1 (enExample)
SI (1) SI3769753T1 (enExample)
SM (1) SMT202200082T1 (enExample)
TW (1) TWI864053B (enExample)
WO (1) WO2021014348A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020317084A1 (en) * 2019-07-23 2022-03-03 Nicox Ophthalmics, Inc. Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
CN115887372A (zh) * 2022-10-25 2023-04-04 苏州欧康维视生物科技有限公司 丙酸氟替卡松混悬液及其制备方法
CN115554238A (zh) * 2022-10-25 2023-01-03 苏州欧康维视生物科技有限公司 眼用混悬液及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002177369A (ja) 1992-05-06 2002-06-25 Alcon Lab Inc 眼科用組成物におけるホウ酸塩−ポリオール複合体の使用
JP2008538823A (ja) 2005-04-11 2008-11-06 アドバンスト メディカル オプティクス， インコーポレーテッド 緩衝系としてのボレート−ポリオール混合物
US20130065888A1 (en) 2011-08-15 2013-03-14 Biserka Cetina-Cizmek Ophthalmic formulations and processes for their preparation
JP2015520149A (ja) 2012-05-08 2015-07-16 アシエクス セラピューティクス インコーポレイテッドＡｃｉｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 疎水性治療剤の調製物、製造方法およびその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US6900184B2 (en) * 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
US8010032B2 (en) * 2005-05-23 2011-08-30 Xerox Corporation Fuser member comprising deflocculated material
WO2010141834A1 (en) 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
CA2893654A1 (en) * 2012-12-17 2014-06-26 Glaxo Group Limited Combination of levocabastine and fluticasone furoate for the treatment of inflammatory and/or allergic conditions
TWI773641B (zh) 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑
AU2020317084A1 (en) * 2019-07-23 2022-03-03 Nicox Ophthalmics, Inc. Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002177369A (ja) 1992-05-06 2002-06-25 Alcon Lab Inc 眼科用組成物におけるホウ酸塩−ポリオール複合体の使用
JP2008538823A (ja) 2005-04-11 2008-11-06 アドバンスト メディカル オプティクス， インコーポレーテッド 緩衝系としてのボレート−ポリオール混合物
US20130065888A1 (en) 2011-08-15 2013-03-14 Biserka Cetina-Cizmek Ophthalmic formulations and processes for their preparation
JP2015520149A (ja) 2012-05-08 2015-07-16 アシエクス セラピューティクス インコーポレイテッドＡｃｉｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 疎水性治療剤の調製物、製造方法およびその使用

Also Published As

Publication number Publication date
RS62932B1 (sr) 2022-03-31
PT3769753T (pt) 2022-02-15
AU2020317084A1 (en) 2022-03-03
WO2021014348A1 (en) 2021-01-28
TW202116326A (zh) 2021-05-01
US11406596B2 (en) 2022-08-09
EP3769753A1 (en) 2021-01-27
SI3769753T1 (sl) 2022-04-29
MD3769753T2 (ro) 2022-04-30
SMT202200082T1 (it) 2022-03-21
MX420447B (es) 2025-02-10
JP7494230B2 (ja) 2024-06-03
CN111821261B (zh) 2022-07-26
DK3769753T3 (da) 2022-01-31
HUE057416T2 (hu) 2022-05-28
US20210023001A1 (en) 2021-01-28
CN115120557A (zh) 2022-09-30
EP3769753B1 (en) 2021-11-17
JP2022062172A (ja) 2022-04-19
HRP20220165T1 (hr) 2022-04-29
ES2905793T3 (es) 2022-04-12
CN115120557B (zh) 2024-05-07
MX2022000928A (es) 2022-02-22
KR20220038443A (ko) 2022-03-28
PH12022550003A1 (en) 2022-11-14
JP2021017449A (ja) 2021-02-15
CN111821261A (zh) 2020-10-27
US20220241296A1 (en) 2022-08-04
US20220323352A1 (en) 2022-10-13
CY1124930T1 (el) 2023-01-05
TWI864053B (zh) 2024-12-01
CA3145055A1 (en) 2021-01-28
PL3769753T3 (pl) 2022-04-04
LT3769753T (lt) 2022-05-10

Similar Documents

Publication Publication Date Title
JP5558582B2 (ja) 眼科用医薬組成物の調製方法
JP7494230B2 (ja) 無菌眼用水性プロピオン酸フルチカゾンａ型ナノ結晶懸濁液の調製方法
JP2019535798A (ja) 眼科用活性医薬成分送達のためのシクロデキストリン固体複合体の製造
CN107847432A (zh) D2o稳定化的药物制剂
CN107613985A (zh) 含有糖皮质激素的纳米微粒的水性悬浮液剂
CN104814924A (zh) 一种布佐林胺脂质体眼用制剂及其制备方法
JP2013508420A (ja) 点眼製剤およびその製造方法
CN104721136A (zh) 一种布佐林胺眼用纳米混悬剂及其制备方法
HK40077423A (en) Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
HK40077423B (zh) 用於制备无菌眼用水性丙酸氟替卡松a型纳米晶体混悬液的方法
HK40038382A (en) Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
HK40038382B (en) Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
CN104721130B (zh) 一种布林佐胺包合物眼用制剂及其制备方法
CN106714803A (zh) 眼用混悬液制剂
JP7641566B2 (ja) 超微細化水難溶性薬物及び水溶性薬物を含む点眼剤並びにその製造方法及び使用方法
WO2022195382A1 (en) A stable ophthalmic nanosupension of brinzolamide
WO2025144421A1 (en) Aqueous nanomicelle ophthalmic formulations containing difluprednate
WO2025220660A1 (ja) チボザニブ原薬およびその製造方法
JP2024507326A (ja) 点眼投与により乾燥型黄斑変性症および網膜光障害を予防・治療するための眼科用製剤
CN116669718A (zh) 用于改善或预防视网膜循环障碍以及视网膜神经血管连接障碍的滴眼剂
HK1234413B (zh) 用於治療眼部病症的膜附著性自組裝體系
HK1233540A1 (en) Ophthalmic suspension formulation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211111

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20211111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220203

R150 Certificate of patent or registration of utility model

Ref document number: 7021301

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250